Skip to Main Content
Contribute Try STAT+ Today

One of the priorities of the new Biden administration is to tackle the cost of prescription medicines, an elusive goal for many federal and state lawmakers over the past several years. However, Christopher Morten has a suggestion. As the deputy director at the New York University Technology Law and Policy Clinic, he studies patents and access to medicines. In collaboration with PrEP4All, an AIDS activist group, and three of his students, Morten has just published a “user’s guide’” to a federal law that he believes could help lower drug costs. The focus is on Section 1498, which would allow the U.S. government to use patents and compensate the owners. Unlike march-in rights, the idea has gotten little attention, but he argues its time may have come. This is an edited version of our conversation. 

So what is Section 1498?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.